Tempest Therapeutics, Inc. — Director's Dealing 2014

Jun 5, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2014-06-03

Reporting Person: Stock Harald F. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-06-03	Common Stock	P	1063	$7.0099	Acquired	8013	Indirect

Footnotes

F1: The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

F2: By SB Vermogensverwaltungs KG, an investment company of which the reporting person is a majority shareholder and managing partner.